Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06OFS
|
||||
| Former ID |
DIB006425
|
||||
| Drug Name |
Rilmenidine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension [ICD9: 401; ICD10:I10-I16] | Approved | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H19N2O5P
|
||||
| Canonical SMILES |
C1CN=C(NC(C2CC2)C3CC3)O1
|
||||
| InChI |
1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
|
||||
| InChIKey |
CQXADFVORZEARL-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Modulator | [2], [1] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.